INDV (Indivior Pharmaceuticals) Institutional Ownership: 112.77% (As of Jul. 11, 2026)


INDV Indivior Pharmaceuticals Inc INDV
69 GF Score
Price $40.50
GF Value $22.94
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Institutional Ownership?

Indivior Pharmaceuticals INDV -1.94% 69 Institutional Ownership is 112.77% as of Jul. 11, 2026. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.94 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Indivior Pharmaceuticals's institutional ownership is 112.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Indivior Pharmaceuticals's Insider Ownership is 2.14%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Indivior Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 84.18%.

Indivior Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Institutional Ownership Chart

Indivior Pharmaceuticals Historical Data

The historical data trend for Indivior Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 23.04 26.06 30.15 45.76 45.90 46.14 55.93 57.02 59.95 60.24
INDV
69GF Score
Indivior Pharmaceuticals Inc INDV
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 112.77% mean?
Indivior Pharmaceuticals (INDV) has a Institutional Ownership of 112.77% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' Institutional Ownership too high?
Indivior Pharmaceuticals' current Institutional Ownership is 112.77%. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Institutional Ownership compare to KNSA and AMRX?
Indivior Pharmaceuticals' Institutional Ownership of 112.77% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Institutional Ownership is 112.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.94, compared to a current price of $40.50 — trading 76.5% above its estimated fair value. The current Institutional Ownership is 112.77%. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Institutional Ownership is 112.77% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $40.50 is trading 76.5% above its estimated GF Value™ of $22.94. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Institutional Ownership: 112.77%
  • GF Value™: $22.94 vs. price of $40.50 (76.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
69GF Score

Get the complete analysis for INDV

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.50
Price
$22.94
GF Value